Navigation Links
Lialda in Medical News

Long-term safety data on Lialda published in leading GI journal

Basingstoke, UK and Philadelphia, US June 17, 2008 Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced the publication of data from a randomized, long-term safety and tolerability study (study 303) of ulcerative colitis (UC) drug Lialda™...

New Analyses of long-term LIALDA (mesalamine) data presented at ACG

Philadelphia, PA October 15, 2007 Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate u...

Shire Expands Gastrointestinal Patient Assistance Program for Uninsured or Unemployed Americans

...nts who are newly prescribed or are already taking lialda or Pentasa and who become unemployed in 2009 can r...ar. In addition, more UC patients can benefit from lialda and Pentasa because Shire has raised the household...am (not valid in Mass.) and a 30-day free trial of lialda when patients join the...

Humira to Replace Remicade as First Choice Among Biologics for the Treatment of Crohn's Disease

...rapy for patients with mild disease. Among oral 5-aminosalicylates, Shire's lialda has more convenient dosing. Because of this clinical advantage, surveyed physicians indicated that they intend to move patients to lialda from both Procter & Gamble/Giuliani's Asacol and Shire/Ferring/Nisshin/Kyor...

Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal

...tudy were to assess the safety and tolerability of lialda in mild-to-moderate UC patients over 12 months. Da...terology. "This published data demonstrates that lialda is generally well tolerated and has a strong safet... the 303 study show that a majority of patients on lialda continued to remain in remission through 12 months...

Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis

...ith UC will develop colon cancer. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Nationwide survey reveals differing physician and patient perceptions regarding impact of UC

...tions on Remission Management and Lifestyle), were sponsored by Shire Pharmaceuticals, a specialty biopharmaceutical company, which markets once-daily lialda and PENTASA (mesalamines) for UC. Before these surveys, patient and physician views on UCs impact had not been compared and the real-life impact o...

Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients' Lives

...ssen the burden," said Dr. Rubin. About LIALDA lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...e, mild to moderate UC. The safety and efficacy of lialda have been established for up to eight weeks. LIALD...

Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track

... 43.7 18% 2% 17% lialda 16.3 n/a n/a ...price increases in November 2006 and August 2007. lialda - Ulcerative colitis Shire launched lialda during March 2007. By September 30, 2007 LIALDA ha...

LIALDA demonstrates prolonged release of mesalamine in an in vitro study using a simulated colon

..., NASDAQ: SHPGY, TSX: SHQ) ulcerative colitis drug lialda (mesalamine) demonstrated a delivery system where ...erative colitis. In this in vitro model, after the lialda tablet passed through the simulated stomach, small...n adult GI tract, we were able to demonstrate that lialda tablets provide maximum release of 5-ASA in a prol...
Lialda in Medical Technology

Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of Lialda (mesalamine) Presented at DDW

Post-hoc analysis shows nearly nine out of ten patients taking once-daily Lialda remained relapse free at the end of 12 months WASHINGTON, D.C., May 22, 2007 /PRNewswire-FirstCall/ -- A long-term phase III, open-label 12-14 month extension study (303) presented at the British Society of Gastroente...

Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week

... of therapy for continuing patients, 20 percent of lialda patients were continually persistent, 9 percent of...tion of the prescription that preceded the refill. lialda is an FDA-approved, once-daily oral medication for...cerative colitis (UC). Safety and effectiveness of lialda beyond eight weeks have not been established. ...

Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW

...om St Mark's Hospital in London, UK), demonstrated lialda was effective in inducing remission in patients wi... 8-week study. Patients in the Kamm study received lialda 2.4g/day once daily (n=84), 4.8g/day once daily (n... the definition used for remission, treatment with lialda 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted...

New Analyses of Long-Term LIALDA(TM) (mesalamine) Data Presented at ACG

...ug LIALDA(TM) (mesalamine) provide further data on lialda in patients with mild to moderate ulcerative colit...3 was safety and tolerability and findings -- that lialda is generally well tolerated in mild to moderate UC...tland in March 2007. "Earlier studies showed that lialda is well-tolerated and effective at inducing remiss...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life

... people with UC will develop colon cancer. About lialda lialda is part of a drug class called aminosalicylates, w...of choice and often a first-line treatment for UC. lialda is indicated for the induction of remission in pat...
Lialda in Biological Technology

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... 4.9 n/a n/a n/a(5) n/a(5) lialda / MEZAVANT 54.6 71% 73% ... 54.0 44.8 21% 8% lialda / MEZAVANT 54.6 32.0 7... 105.2 89.0 18% 7% lialda / MEZAVANT 104.0 59.2 76...

Shire begins the year with a strong performance

...ncome within revenues. License agreement for lialda in Japan - On January 16, 2009 Shire announce...LDA(R) (mesalamine) in Japan. Termination of lialda co-promotion agreement - As of March 31, 2009...tical Products Inc., for the co-promotion of lialda in the US. Pipeline DAYTRANA - for the t...

Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion

... Pharmaceutical Co., Ltd to develop and sell lialda in Japan. - On February 9, 2009 Shire announc... 78.7 +23% -11% 1.8% lialda / MEZAVANT 140.4 +178% +204% ...er 31, 2008 (2007: 21.1%), driven by the growth of lialda since its launch in March 2007. LIALDA/MEZA...

Shire's New Product Portfolio Delivers Strong Quarterly Performance

... first time. The performance of ELAPRASE, VYVANSE, lialda and FOSRENOL ROW were particularly strong. This qu... 18.1 93% -14% 1.6% lialda / MEZAVANT 40.4 148% +143% ...er 30, 2008 (2007: 22.5%), driven by the growth of lialda since its launch in March 2007. The overall US ora...

Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.

...oduct sales comprise DAYTRANA, ELAPRASE, FOSRENOL, lialda / MEZAVANT and VYVANSE Angus Russell, Chief...Products Inc. ("TAP") commenced co-promotion of lialda in the US in accordance with the co-promotion a... 22.6 14% -11% 1.8% lialda / MEZAVANT 32.0 n/a n/a ...

Cadient Group Recognized with Five Awards at 14th Annual Communicator Awards

...mpaigns." Cadient Group received the following Communicator Awards: -- lialda - Silver Communicator Award Cadient Group was recognized for its work with Shire US, Inc.'s lialda Web site, which offers information, tools, and resources for people ...

Following a Good Start to the Year Shire Reaffirms Full Year 2008 Financial Guidance

...uency of our sales calls. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...VANT(R) - Ulcerative Colitis - By April 11, 2008 lialda had achieved a 9.8% share of the US oral mesalamin...hire's share of the US oral mesalamine market from lialda and PENTASA combined increased to 26.1% for the th...

Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine For Patients With Active, Mild to Moderate Ulcerative Colitis

...of 120 representatives who are currently detailing lialda primarily to gastroenterologists. "Aligning with...mendous benefit for Shire as it will quadruple the lialda sales force across the United States," said Mike Y...th messages about Lialda. Shire's GI team has made lialda the fastest growing brand of mesalamine and with t...

Shire plc: IFRS Results for the Year Ending December 31, 2007

...LDA/MEZAVANT - Ulcerative colitis Shire launched lialda in the US oral mesalamine market in March 2007, and by December 31, 2007 lialda had reached a market share of 8.0% (average annual...were US$50.5 million. All initial launch stocks of lialda totaling US$34.3 million were recognised into reve...

Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

...ertook three major new product launches - VYVANSE, lialda / MEZAVANT and DYNEPO - which have gone well and a...hire's share of the US oral mesalamine market from lialda and PENTASA(R) combined was 26.0% at February 8, 2... 176.4 +28% +3% 17.2% lialda 50.5 n/a n/a ...
Other Tags
(Date:1/23/2015)... 2015 Hastings and Hastings, a law firm ... record number of legal representation client review requests for slip ... a steady rise in the number of slip and fall ... throughout the Valley. With that said, a large number of ... an experienced law firm. Hastings and Hastings is a personal ...
(Date:1/22/2015)... with its top dressmaking technologies, has been a leading dress ... its latest designs of wedding dresses and launching a site-wide ... all the fresh new products are designed for 2015, and ... off. All the clothes from LunaDress follow up with the ...
(Date:1/22/2015)... Padre Murphy's and Owner Tom Boyle in Glendale, AZ ... Alliance (PPHA). The PPHA's passion for others' well-being and ... greats, treated for obstructive sleep apnea (OSA) has propelled them ... in the valley. The most recent plans for an event ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
Breaking Medicine News(10 mins):Health News:Hastings and Hastings Reports a Record Number of Client Review Requests for Slip and Fall Accidents in 2014 2Health News:LunaDress Shows The Latest Styles Of Wedding Dresses In 2015 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 2Health News:Padre Murphy's Holds NFL Retired Players Association Party Star Studded Event With Bud Light and Pro Player Health Alliance Sponsoring 3Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3
(Date:1/22/2015)... ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform its shareholders ... Washington,s Department of Licensing, in the United States, awarded ... for driver,s licenses and identification cards to its subsidiary, Valid ... start in January 2015, with enrollment and card production starting ...
(Date:1/22/2015)... Wis. , Jan. 15, 2015  BellBrook Labs, ... drug discovery, announced the launch of a TR-FRET ... the company,s Transcreener UDP Assay, a high throughput ... The new assay will allow for sensitive detection ...
(Date:1/22/2015)... 2015  Analyst Report Issued by Small Cap IR. In 2011, ... planet-wide, transactions at merchants on the leading payment cards rose ... credit, debit, and prepaid cards reached 6.54 billion.  Eight million ... card usage in 2012, and credit and debit card fraud ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2
Other Contents